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Introduction:	   Patients	   with	   cystic	   fibrosis	   (CF)	   are	   more	   susceptible	   to	   pathogens	   like	   P.	  
aeruginosa	   (PA).	   PA	   primo-­‐infections	   require	   particular	   attention,	   as	   with	   failure	   in	  
eradication,	  there	  is	  accelerated	  lung	  deterioration.	  The	  main	  aim	  of	  this	  study	  is	  to	  assess	  
the	  rate	  of	  PA	  eradication	  according	  to	  our	  particular	  protocol	  with	  inhaled	  tobramycin	  and	  
oral	  ciprofloxacin,	  as	  there	  is	  no	  consensus	  in	  the	  literature	  on	  what	  eradication	  protocol	  the	  
best	  is.	  
Methods:	  Retrospective	  single	  centre	  study	  with	  data	  analysis	  from	  June	  1st	  2007	  to	  June	  1st	  
2011	   of	   patients	   who	   had	   primo-­‐infections	   exclusively	   treated	   by	   3	   x	   28	   days	   of	   inhaled	  
tobramycin	   and	   oral	   ciprofloxacin	   for	   the	   first	   and	   last	   21	   days.	   Success	   in	   eradication	   is	  
defined	  by	  ≥	  3	  negative	  bacteriologies	  for	  6	  months	  after	  the	  beginning	  of	  the	  protocol.	  If	  ≥	  1	  
bacteriology	  is	  positive,	  we	  consider	  the	  eradication	  as	  a	  failure.	  	  
Results:	  Out	  of	   41	   patients,	   18	  were	   included	   in	   our	   analysis.	   7	   girls	   (38.9%)	   and	  11	  boys	  
(61.1%)	   followed	   the	   eradication	   protocol.	   Boys	   had	   12	   primo-­‐infections	   and	   girls	   had	   8.	  
Among	   these	  20	  primo-­‐infections,	  16	   (80%)	  had	  an	  all-­‐overall	   success	   in	  eradication	  and	  4	  
(20%)	  a	   failure.	  No	   significant	   statistical	   difference	   for	   age	  between	   these	  groups	   (t-­‐test	   =	  
0.07,	  p	  =	  0.94),	  neither	  for	  FEV1%	  (t-­‐test	  =	  0.96,	  p	  =	  0.41)	  nor	  BMI	  (t-­‐test	  =	  1.35,	  p	  =	  0.27).	  
Rate	  of	  success	  was	  100%	  for	  girls	  and	  66.6%	  for	  boys.	  	  
Conclusion:	  Our	  protocol	  succeeded	  in	  an	  overall	  eradication	  rate	  of	  80%,	  without	  statistical	  
significant	   impact	   on	   FEV1	   %	   and	   BMI	   values.	   However,	   there	   is	   a	   sex	   difference	   with	  
eradication	   rates	   in	   girls	   (100%)	   and	   boys	   (66.6%).	   A	   sex	   difference	   has	   not	   yet	   been	  
reported	  in	  the	  literature.	  This	  should	  be	  evaluated	  in	  further	  studies.	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1.1 Cystic	  fibrosis	  generalities	  
1.1.1 Genetic	  
Cystic	  fibrosis	  (CF)	  is	  the	  most	  common	  autosomal	  recessive	  disease	  (1).	  In	  Switzerland,	  the	  
prevalence	   is	   around	  1	   to	  2900	   (2).	   The	  number	  of	   asymptomatic	  heterozygote	   carriers	   is	  
approximately	  4%,	  with	  a	  25%	  probability	  that	  two	  asymptomatic	  heterozygote	  carriers	  give	  
birth	  to	  a	  homozygote	  child	  (1).	  
CF	  is	  caused	  by	  a	  mutation	  on	  the	  long	  arm	  of	  chromosome	  7.	  The	  concerned	  gene	  code	  for	  
a	   protein:	   the	   cystic	   fibrosis	   transmembrane	   conductance	   regulator	   (CFTR).	   Since	   the	  
discovery	  of	  the	  implicated	  gene	  in	  1989	  (1),	  over	  1800	  mutations	  have	  been	  described,	  with	  
grouping	  the	  mutations	  in	  five	  classes	  (3):	  
• Class	  I:	  CFTR	  is	  not	  produced	  because	  of	  nonsense,	  frameshift	  or	  splice	  mutations	  
• Class	  II:	  CFTR	  is	  abnormally	  folded	  and	  is	  recognized	  to	  be	  destroyed	  
• Class	  III:	  CFTR	  has	  a	  regulation	  defect	  
• Class	  IV:	  CFTR	  has	  an	  abnormal	  conductance	  for	  chloride	  
• Class	  V:	  CFTR	  is	  correctly	  produced,	  but	  in	  reduced	  quantity	  
The	  most	  common	  mutation	  found	  in	  Switzerland,	  a	  deletion	  of	  phenylalanine	  in	  the	  amino	  
acid	  position	  508	  (F508	  deletion)	  forms	  a	  part	  of	  the	  class	  II	  (1,4).	  
1.1.2 General	  physiopathology	  
CFTR	  is	  located	  on	  the	  apical	  membrane	  of	  epithelial	  cells.	  In	  physiologic	  conditions,	  agonists	  
(A)	  –	  like	  acetylcholine	  –	  bind	  to	  receptors	  (R)	  on	  the	  epithelial	  cells	  and	  increase	  the	  cyclic	  
adenosine	   monophosphate	   (cAMP).	   cAMP	  
activates	   the	   protein	   kinase	   A	   (PKA).	   PKA	  
phosphorylates	   the	   CFTR.	   The	   phosphorylated	  
CFTR	   permits	   the	   chloride	   transport	   (5).	   It	  
regulates	  others	  ion	  channels	  (6).	  
In	   the	   sweat	   glands,	   chloride	   is	   less	   or	   not	  
reabsorbed	   by	   defective	   CFTR	   from	   the	   lumen.	  
Sodium	   stays	   in	   the	   lumen	   too.	   Therefore,	   the	  
sweat	   has	   an	   increased	   concentration	   in	   chloride	  
and	  sodium	  (5).	  
In	  the	  normal	  exocrine	  pancreas,	  the	  apical	  membrane	  of	  epithelial	  cells	  ejects	  chloride	  and	  
absorbs	   bicarbonate.	   Then,	   chloride,	   sodium	   and	   water	   diffuse	   passively	   out	   the	   cells.	  
Defective	  CFTR	  limits	  this	  and	  the	  pancreatic	  enzymes	  are	  retained	  in	  the	  cells	  too.	  Finally,	  
these	   mechanisms	   destroy	   the	   pancreatic	   tissue	   and	   cause	   an	   exocrine	   pancreatic	  
insufficiency	  responsible	  for	  malnutrition	  (6).	  
In	  the	  intestine,	  deficient	  CFTR	  decreases	  proximal	  liquid	  secretions	  and	  increases	  their	  distal	  
absorption.	   Both	   anomalies	   lead	   to	   the	   desiccation	   of	   the	   intestinal	   content	   and	   to	   the	  
Figure	  1:	  CFTR	  function	  in	  physiologic	  conditions,	  
adapted	  from	  Cotran	  et	  al.	  (5)	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obstruction	   of	   the	   lumen.	   In	   newborns,	   they	  manifest	   in	  meconium	   ileus.	   In	   childhood	   or	  
early	  adulthood,	  distal	  obstruction	  of	  the	  intestine	  is	  possible	  (6).	  
In	   the	   liver,	  abnormal	  CFTR	  causes	  bile	   retention,	  which	   is	   responsible	   for	   cirrhosis.	   In	   the	  
gallbladder,	  water	  and	  NaCl	  are	  less	  secreted,	  causing	  cholecystitis	  and	  gallstones	  (6).	  
Chronic	   manifestations	   in	   the	   airways	   (see	   part	   1.2.1)	   and	   malnutrition	   affect	   endocrine	  
reproductive	   function.	  As	  a	   result,	   the	  puberty	   is	  often	  delayed	  and	  the	  menstrual	  cycle	   is	  
sometimes	   slowed.	   As	   a	   consequence	   of	   inefficient	   CFTR,	   most	   of	   men	   suffer	   from	  
azoospermia	  caused	  by	  the	  obliteration	  of	  vasa	  deferentia,	  some	  women	  are	  sterile	  because	  
of	  abnormal	  mucus	  in	  the	  fallopian	  tubes	  and	  anomalies	  of	  liquids	  transport	  in	  the	  fallopian	  
tubes	  and	  in	  the	  uterus	  (6).	  
1.1.3 Diagnosis	  of	  cystic	  fibrosis	  	  
Nowadays,	   the	   diagnosis	   of	   CF	   is	   based	   on	   newborn	   screening	   (NBS),	   introduced	   in	  
Switzerland	   on	   January	   1st	   2011.	   NBS	   for	   CF	  was	   added	   to	   the	   Guthrie	   test,	   a	   blood	   test	  
performed	   72	   to	   96	   hours	   after	   birth,	   which	   already	   screened	   for	   phenylketonuria,	  
galactosaemia,	   biotinidase	   deficiency,	   medium-­‐chain	   acyl-­‐coenzyme	   A	   dehydrogenase	  
deficiency,	  congenital	  hypothyroidism	  and	  congenital	  adrenal	  hyperplasia	  (7).	  	  
NBS	   for	  CF	   is	  based	  on	   the	   immunoreactive	   trypsinogen	   test	   (IRT),	  a	   test	  already	  available	  
since	  1980	  (8).	  Children	  with	  an	  elevated	  IRT	  are	  considered	  as	  positive	  in	  NBS.	  To	  confirm	  
respectively	  to	  rule	  out	  the	  diagnosis	  of	  CF,	  every	  country	  has	  its	  specific	  algorithm,	  including	  
the	  sweat	  test	  and	  the	  genetic	  analysis	  (7).	  	  
In	   childhood,	   NBS	   prevents	  malnutrition	   with	   profits	   to	   growth,	   cognitive	   and	   pulmonary	  
functions.	   It	   allows	   families	   a	   consented	   decision	   about	   performing	   an	   amniocentesis	   in	  
following	  pregnancies.	  However,	   it	   is	   still	   less	  clear	   if	   there	  are	  
significant	  benefits	  of	  NBS	  on	  pulmonary	  function	  later	  in	  life	  in	  
adult	  patients	  (9).	  	  
The	   very	   first	   clinical	   manifestation,	   present	   at	   birth,	   is	  
meconium	   ileus.	   Otherwise,	   the	   clinical	   diagnosis	   of	   CF	   in	  
patients	  born	  prior	  to	  the	  introduction	  of	  NBS	  for	  CF	  is	  based	  on	  
symptoms	   like	   recurrent	   cough,	   failure	   to	   thrive,	   steatorrhea,	  
chronic	  abdominal	  pain,	  chronic	  rhinosinusitis	  and	  nasal	  polyps.	  
Those	  symptoms	  can	  appear	  months	  or	  years	  after	  birth	  (7).	  
Three	  methods	  are	  available	  to	  confirm	  the	  diagnosis.	  The	  gold	  
standard	   is	   the	   sweat	   test.	   It	   measures	   the	   concentration	   of	  
chloride	  in	  sweat.	  The	  test	  is	  pathologic	  if	  the	  concentration	  is	  ≥	  
60	  mmol/L.	  The	  genetic	  analysis	  demonstrates	   the	  presence	  of	  
two	  mutations	  on	  the	  CFTR	  gene.	   In	  some	  clinical	  situations	   it	  might	   lastly	  be	  necessary	  to	  
measure	   the	  nasal	  potential	   difference,	   a	  method	   to	  analyse	   the	  CFTR	   function	  directly	   in	  
the	  nasal	  epithelium	  (4).	  
Figure	  2:	  CF	  diagnosis	  algorithm,	  
adapted	  from	  Barben	  et	  al.	  (7)	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1.2 Cystic	  fibrosis	  lung	  disease	  
1.2.1 Specific	  CFTR	  physiopathology	  in	  the	  airways	  
According	   to	   the	  mutation	   class,	   CFTR	   is	   either	  not	  produced	  or	   less	   functional	   (3).	   In	   the	  
airways,	  it	  means	  that	  chloride	  is	  less	  or	  not	  secreted	  into	  the	  lumen.	  This	  is	  accompanied	  by	  
an	   increased	   active	   transport	   of	   sodium.	   Both	   phenomena	   lead	   to	   an	   augmented	  
reabsorption	  of	  water	  from	  the	  airway	  lumen	  to	  the	  epithelial	  cells.	  As	  a	  result,	  the	  airway	  
surface	  liquid	  (ASL)	  is	  depleted	  and	  the	  mucociliary	  clearance	  decreases	  (5).	  
	  
Figure	  3:	  CFTR	  in	  lung	  cells,	  in	  physiologic	  and	  pathologic	  conditions,	  adapted	  from	  Cotran	  et	  al.	  (5)	  
1.2.2 Infections	  and	  inflammation	  in	  CF	  airways	  
1.2.2.1 Generalities	  on	  infections	  
CF	   lungs	   are	   more	   susceptible	   to	   infections.	   In	   early	   childhood,	   S.	   aureus	   (SA)	   and	   H.	  
influenzae	  (HI)	  are	  frequently	  isolated.	  The	  presence	  of	  P.	  aeruginosa	  (PA)	  increases	  with	  age.	  
Approximately	  80%	  of	  patients	  at	  age	  of	  20	  years	  old	  are	  infected	  by	  PA	  (10).	  Even	  if	  CF	  is	  a	  
systemic	   disease,	   airways	   manifestations,	   particularly	   aggravated	   by	   PA	   infections,	   weigh	  
heavily	  on	  morbidity	  and	  mortality	  (11).	  
	  
Figure	  4:	  epidemiology	  of	  infections	  in	  CF	  lungs,	  adapted	  from	  Koch	  et	  al.	  (10)	  
1.2.2.2 Generalities	  on	  PA	  
PA	   is	   a	  motile,	   aerobe,	   non-­‐fermentative	   and	   gram-­‐negative	   rod.	   Even	   if	   this	   bacterium	   is	  
ubiquitous,	  uses	  many	  sources	  of	  carbon	  and	  nitrogen	  and	   is	  highly	  virulent,	   it	   remains	  an	  
opportunistic	   pathogen.	   Most	   of	   the	   time,	   it	   affects	   hosts	   with	   compromised	   defences,	  
typically	  CF	  patients	  (12).	  
Many	  virulence	  factors,	  as	  structural	  components,	  toxins	  and	  enzymes,	  render	  PA	  resistant	  
to	  most	  common	  antibiotics.	  This	   resistance	   is	  often	  caused	  by	  mutations	  of	  porins.	  These	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mutations	   prevent	   antibiotics	   to	   penetrate	   into	   the	   cell.	   Moreover,	   PA	   β-­‐lactamases	  
inactivate	  many	  β-­‐lactam	  antibiotics	  (12).	  
	  
Table	  1a:	  PA	  virulence	  factors	  –	  structural	  components,	  adapted	  from	  Murray	  et	  al.	  (12)	  
	  
Table	  1b:	  PA	  virulence	  factors	  –	  toxins	  and	  enzymes,	  adapted	  from	  Murray	  et	  al.	  (12)	  
1.2.3 From	  PA	  primo-­‐infection	  to	  chronic	  colonisation	  in	  CF	  airways	  
PA	   can	   sometimes	   be	   found	   in	   the	   oropharyngeal	   tract	   and	   from	   there,	   go	   intermittently	  
into	   the	   tracheobronchial	   tract	   (13).	   The	   first	   identification	   of	   PA	   in	   CF	   patients	   is	   called	  
primo-­‐infection	  witch	  potentially	  have	  a	  response	  to	  the	  treatments	  (11).	  Depending	  on	  the	  
defined	  free	  interval,	  patients	  can	  have	  a	  second,	  third	  or	  more	  PA	  primo-­‐infections.	  
In	   the	   tracheobronchial	   tract,	   CFTR	   is	   deficient	   (3)	   and	   the	   mucociliary	   clearance	   is	  
decreased	  (5).	  Both	  phenomena	  prevent	  from	  PA	  internalisation	  and	  destruction.	  PA	  affinity	  
for	  epithelial	  cells	  receptors	  is	  increased	  (14).	  After	  PA	  bound	  to	  these	  cells,	  it	  proliferates.	  If	  
it’s	  not	  adequately	  treated,	  at	  a	  certain	  density,	  proliferation	  decreases	  with	  differentiation	  
of	  PA.	   It	  forms	  a	  biofilm,	  which	  is	  a	  complex	  of	  several	  bacteria	  surrounded	  by	  a	  polymeric	  
matrix	  (11).	  This	  matrix	  is	  constituted	  by	  alginate	  polysaccharide	  (13).	  Biofilm	  production	  is	  
induced	  by	   the	   change	  of	  PA	   lateral	   chain	   from	   smooth	   lipopolysaccharide	   to	   rough,	  with	  
appearance	  of	  PA	  on	  the	  agar	  plate	  as	  mucoid	  (14).	  
Moreover,	  PA	   induces	   the	   inflammation	   (15),	  which	   is	  more	   stimulated	  once	  PA	   becomes	  
mucoid	  (14).	  
3	   months	   of	   PA	   persistence	   could	   be	   enough	   to	   lead	   to	   the	   transformation	   of	   PA	   in	   its	  
mucoid	  form,	  making	  an	  eradication	  by	  antibiotics	  more	  difficult	  (11),	  resulting	  in	  a	  chronic	  
colonisation	  (14).	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1.2.4 Diagnosis	  of	  PA	  in	  the	  airways	  
CF	  lung	  disease	  –	  worsened	  by	  PA	  colonisation	  –	  has	  the	  biggest	  influence	  on	  morbidity	  and	  
mortality	   (11).	   Therefore,	   early	   detection	   of	   PA	   is	   fundamental,	   in	   order	   to	   eradicate	   it	  
before	  reaching	  the	  mucoid	  stage	  (16).	  Samples	  are	  taken	  at	  least	  every	  3	  months	  during	  the	  
routine	   follow-­‐up	   of	   outpatient	   clinics,	   or	   in	   case	   of	   pulmonary	   exacerbations.	   Several	  
methods	  to	  get	  a	  bacteriological	  sample	  exists	  (14):	  
• Throat	  swaps	  are	  used	  for	  children	  who	  can’t	  expectorate	  (11).	  
• Sputum	   sample	   is	   the	   common	   choice	   for	   older	   children	   or	   adults	   who	   can	  
expectorate	   (11).	   Induced	   expectoration	   is	   possible	   after	   inhalation	   of	   hypertonic	  
saline	  solution	  or	  physiotherapy	  (13).	  
• Bronchoalveolar	   lavage	   (BAL)	   is	   an	   invasive	   method	   (11)	   that	   requires	   a	   general	  
anaesthesia	  in	  children.	  It	  can	  be	  used	  in	  young	  children	  who	  can’t	  expectorate	  (13).	  
However,	   a	   recent	   study	   showed	   that	   this	   invasive	   method	   in	   case	   of	   pulmonary	  
exacerbations	  is	  not	  better	  in	  detection	  of	  pathogens	  than	  a	  throat	  swap	  (17).	  
1.3 Objective	  
1.3.1 Primary	  outcome	  
The	   aim	   of	   our	   study	   is	   to	   retrospectively	   analyse	   the	   success	   rate	   of	   PA	   eradication	   in	  
primo-­‐infections	   treated	   by	   three	  months	   consecutive	   of	   inhaled	   tobramycin	  with	   twice	   a	  
cycle	  of	  oral	  ciprofloxacin	  (see	  part	  2.5.2).	  
1.3.2 Secondary	  outcomes	  
• Analysis	  of	  diagnostic	  methods,	  according	  to	  the	  age	  of	  our	  patients	  
• Analysis	  of	  type	  and	  frequency	  of	  concomitant	  pathogens	  
• Analysis	  of	  PA	  status	  one	  year	  before	  and	  one	  year	  after	  the	  eradication	  therapy	  
• Analyse	   of	   effects	   of	   the	   eradication	   protocol	   on	   forced	   expiratory	   volume	   in	   1	  
second	  expressed	  in	  per	  cent	  (FEV1	  %)	  and	  on	  body	  mass	  index	  (BMI)	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2 METHODOLOGY	  
2.1 Study	  design	  
Retrospective	  single	  centre	  study	  
2.2 Study	  period	  
June	  1st	  2007	  to	  June	  1st	  2011	  
2.3 Study	  population	  
Patients	   with	   a	   confirmed	   diagnosis	   of	   CF	   (clinical	   symptoms	   consistent	   with	   CF	   and	   two	  
positive	   sweat	   tests	   [chloride	  ≥	  60mmol/L]	  or	  a	  genotype	  with	   two	   identifiable	  CF-­‐causing	  
mutations),	  followed	  in	  the	  paediatric	  CF	  outpatient	  clinic	  at	  Lausanne	  University	  Hospital	  in	  
Switzerland	  were	  included	  in	  the	  study.	  
2.3.1 Included	  patients	  
Inclusion	   of	   all	   patients	   who	   fulfilled	   the	   criteria	   for	   primo-­‐infection	   with	   PA,	   treated	  
according	  the	  eradication	  protocol	  (see	  part	  2.5).	  
2.3.2 Excluded	  patients	  
Exclusion	  of	  all	  patients:	  
• With	  uncompleted	  eradication	  protocol	  	  
• With	  adapted	  eradication	  protocol	  
• Who	  got	  intravenous	  (i.v.)	  antibiotics	  in	  addition	  to	  the	  eradication	  protocol	  
• Who	  suffered	  from	  chronic	  PA	  infection	  
• With	  uncompleted	  data	  
• With	  positive	  bacteriological	  culture	  for	  other	  Pseudomonas	  than	  PA	  
2.4 Ethic	  
Ethic	  committee	  approval	  was	  obtained	  on	  April	  20th	  2011.	  
2.5 Definitions	  
For	  analysis,	  we	  used	  the	  following	  definitions:	  
2.5.1 Primo-­‐infection	  with	  PA	  
An	  infection	  with	  PA	  is	  considered	  as	  a	  primo-­‐infection,	  if	  no	  PA	  was	  diagnosed	  for	  the	  last	  6	  
months.	  PA	  was	  identified	  using	  standard	  bacterial	  culture	  methods.	  
2.5.2 Eradication	  protocol	  
Three	   consecutive	   cycles	   of	   inhaled	   tobramycin	   (TOBI®,	   Bramitob®),	   each	   cycle	   defined	   as	  
twice	  daily	   inhalation	  of	  300	  mg	  for	  28	  days	  (“inhalation	  period”).	  Oral	  ciprofloxacin	  (30	  to	  
40	  mg/kg	  body	  weight	  in	  two	  doses	  with	  a	  maximum	  of	  1500	  mg/day)	  was	  added	  during	  the	  
first	  21	  days	  and	  the	  last	  21	  days	  of	  the	  “inhalation	  period”.	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Figure	  5:	  eradication	  protocol	  
2.5.3 Success	  in	  eradication	  
Success	   was	   defined	   when	   ≥	   three	   sputum	   samples	   and/or	   throat	   swaps	   were	   negative	  
during	  a	  6	  months	  period,	  counted	  from	  the	  first	  day	  of	  treatment	  to	  the	  last	  bacteriological	  
sample	  at	  the	  end	  of	  the	  6	  months.	  
	  
Figure	  6:	  success	  and	  failure	  in	  eradication	  rules	  
2.5.4 Failure	  in	  eradication	  
Failure	  was	  defined	  when	  minimum	  at	  least	  one	  sputum	  sample	  and/or	  throat	  swap	  (out	  of	  
three)	   was	   positive	   for	   PA	   during	   the	   period	   of	   6	   months,	   counted	   from	   the	   first	   day	   of	  
treatment	  to	  the	  last	  bacteriological	  sample	  at	  the	  end	  of	  the	  6	  months.	  
2.6 Literature	  review	  
Literature	  review	  was	  performed	  throughout	  summer	  2011,	  with	  these	  Mesh	  terms	  used	  in	  
Pubmed:	  
1. ((cystic	   fibrosis)	   AND	   pseudomonas	   aeruginosa)	   AND	   (((antibiotic)	   OR	   therapy)	   OR	  
treatment)	  
2. 	  ((((cystic	   fibrosis)	   AND	   pseudomonas	   aeruginosa)	   AND	   early	   infection)	   AND	  
tobramycin)	  AND	  administration,	  inhalation)	  
Application	   of	   first	   Mesh	   terms	   revealed	   2121	   citations;	   this	   research	   was	   useful	   to	   find	  
general	  literature	  on	  CF.	  The	  second	  Mesh	  Terms	  (110	  articles	  identified)	  helped	  us	  to	  focus	  
our	  review	  on	  the	  context	  of	  our	  study.	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2.7 Data	  collection	  	  
2.7.1 Data	  sources	  
Data	  collection	  was	  accomplished	  during	  autumn	  2011	  from	  three	  different	  sources:	  
1. Paper	  sheets	  (clinical	  files)	  
2. CF	  FileMaker®	  (in-­‐hospital	  database)	  
3. Archimed	  database	  (hospital	  archives)	  
The	  gathered	  data	  were	  entered	  in	  a	  specific	  created	  FileMaker®	  database.	  Most	  data	  came	  
from	  the	  paper	  sheets.	  The	  CF	  FileMaker®	  database	  was	  used	  to	  complete	  the	  rare	  missing	  
or	   imprecise	   information.	   The	   Archimed	   database	   gave	   more	   information	   particularly	   on	  
hospitalisations.	  	  
2.7.2 Collected	  data	  
• General	  information:	  name,	  age	  and	  sex	  of	  patients	  
• Primo-­‐infection	  according	  definition	  
• Bacteriology	  (type	  of	  PA	  such	  as	  non-­‐mucoid	  or	  mucoid,	  Pseudomonas	  spp,	  …),	  date	  
of	  the	  positive	  result	  
• Eradication	   protocol	   according	   definition:	   doses	   of	   tobramycin	   and	   ciprofloxacin,	  
dates	  of	  beginning	  of	  cycles	  
• Other	  infections:	  type	  of	  pathogens	  one	  year	  before	  and	  one	  year	  after	  the	  diagnosis	  
• Evolution	  of	  patients:	  clinical	  symptoms	  at	  the	  diagnosis,	  during	  the	  treatment	  period,	  
hospitalisation,	  additional	  or	  i.v.	  treatments	  
• Anthropometry:	   weight,	   height,	   body	   mass	   index	   and	   dates	   of	   measures	   of	   these	  
parameters,	  one	  year	  before	  and	  one	  year	  after	  each	  primo-­‐infection	  
• Lung	   function	  parameter:	  FEV1	  %	  and	  dates	  of	  measures,	  one	  year	  before	  and	  one	  
year	  after	  each	  primo-­‐infection	  
2.8 Methodology	  
We	  proceeded	  in	  that	  order:	  
1. First,	  all	  bacteriological	  results	  in	  the	  clinical	  file	  were	  reviewed	  in	  order	  to	  determine	  
which	  patients	  were	  diagnosed	  for	  a	  primo-­‐infection.	  
2. Second,	  still	  with	  the	  paper	  sheets,	  the	  consultations	  letters	  were	  analysed.	  This	  step	  
was	   fundamental	   to	   determine	   –	   among	   the	  patients	  who	  had	   a	   primo-­‐infection	   –	  
who	  were	  treated	  by	  the	  protocol.	  
3. Finally,	  we	  gathered	  other	   information	  on	  patients	   corresponding	   to	   the	   criteria	  of	  
the	  two	  first	  points,	  like	  symptoms,	  hospitalisations,	  FEV1	  %	  and	  anthropometry	  data.	  
Data	  collection	  was	  completed	  from	  fall	  2011	  to	  the	  beginning	  of	  2012.	  All	  patients	  meeting	  
the	  inclusion	  criteria	  were	  classified	  in	  two	  groups:	  “success”	  and	  “failure”,	  according	  to	  our	  
definitions	  (see	  parts	  2.5.3	  and	  2.5.4).	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2.9 Statistical	  analysis	  
	  
Figure	  7:	  FileMaker®	  database	  screenshot	  
Data	   gathered	   in	   our	   FileMaker	   Pro	   11®	   database	   were	   exported.	   Then,	   Microsoft	   Excel	  
2011®	  was	  used	   in	  order	   to	  analyse	   these	  data.	  P	  values	  were	  calculated	  with	   the	  help	  of	  
http://www.stattools.net	  (last	  consult	  in	  August	  2012).	  
2.9.1 Included	  data	  
2.9.1.1 Primary	  outcome	  
2.9.1.1.1 Successes	  or	  failures	  in	  eradication	  
We	   count	   the	   number	   of	   primo-­‐infections	   and	   calculate	   the	   percentage	   of	   successful	  
respectively	  of	  unsuccessful	  eradications.	  We	  determined	  the	  number	  of	  concerned	  patients	  
with	   success	   or	   failure	   in	   eradication	   and	   calculated	   the	  mean	   ±	   standard	   deviation	   (SD),	  
minimum	   and	   maximum	   ages.	   We	   calculated	   the	   percentage	   of	   successes	   or	   failures	  
according	  to	  the	  sex.	  
2.9.1.2 Secondary	  outcomes	  
2.9.1.2.1 Diagnostic	  methods	  
We	   determined	   the	   number	   of	   primo-­‐infections	   diagnosed	   by	   sputum	   samples	   or	   throat	  
swabs.	  We	  calculated	  the	  mean	  ±	  SD,	  minimum	  and	  maximum	  ages	  of	  patients	  according	  to	  
the	  diagnostic	  methods	  used.	  
2.9.1.2.2 Bacterial	  analysis	  
For	   each	   primo-­‐infection,	  we	   determined	   the	  PA	   type	   (mucoid	   or	   not)	   and	   the	   diagnostic	  
method.	  
We	   calculated	   the	   percentage	   of	   concomitant	  microbes	   at	   diagnosis.	  We	   determined	   the	  
percentage	  of	  microbial	  species.	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2.9.1.2.3 PA	  status	  one	  year	  before	  the	  protocol	  
We	   calculated	   the	   percentage	   of	   primo-­‐infections	   preceded	   by	   a	  PA	   detection	   during	   the	  
year	  before	   the	  diagnosis	  and	   the	  mean	  ±	  SD,	  minimum	  and	  maximum	  ages	  of	   concerned	  
patients.	  
2.9.1.2.4 PA	  status	  one	  year	  after	  the	  protocol	  
We	  calculated	  the	  percentage	  of	  PA	  detection	  one	  year	  after	  the	  diagnosis	  and	  the	  mean	  ±	  
SD,	  minimum	  and	  maximum	  ages	  of	  concerned	  patients.	  
2.9.1.2.5 FEV1	  %	  
In	  order	  to	  determine	  if	  the	  FEV1	  %	  values	  change	  after	  the	  primo-­‐infection	  and	  the	  protocol,	  
we	  used:	  
• A	  reference	  value,	  measured	  the	  last	  consultation	  before	  the	  PA	  diagnosis.	  
• Multiple	  comparison	  values,	  measured	  after	  the	  6	  months	  necessary	  to	  determine	  if	  
the	  protocol	  is	  a	  success	  or	  failure.	  
We	  calculated	  the	  mean	  ±	  SD	  and	  the	  median	  of	  references	  values	  and	  of	  comparison	  values.	  
P	  value	  was	  calculated	  with	  a	  t-­‐test.	  
2.9.1.2.6 BMI	  
In	  order	  to	  determine	  if	  the	  BMI	  values	  change	  after	  the	  primo-­‐infection	  and	  the	  protocol,	  
we	  used:	  
• A	  reference	  value,	  measured	  the	  last	  consultation	  before	  the	  PA	  diagnosis.	  
• A	   comparison	   value,	   measured	   after	   the	   6	   months	   necessary	   to	   determine	   if	   the	  
protocol	  is	  a	  success	  or	  failure.	  
We	  calculated	  the	  mean	  ±	  SD	  and	  the	  median	  of	  references	  values	  and	  of	  comparison	  values.	  
P	  value	  was	  calculated	  with	  a	  t-­‐test.	  
2.9.2 Excluded	  data	  
Excluded	  data	  were	  classified	  in	  five	  categories:	  
1. Non-­‐PA	  or	  non-­‐specified	  Pseudomonas	  infections	  treated	  by	  our	  eradication	  protocol	  
2. Infections	  not	  completely	  treated	  by	  the	  protocol	  
3. Infections	  with	  incomplete	  data	  
4. Infections	  treated	  by	  the	  protocol,	  however	  after	  a	  hospitalisation	  for	  i.v.	  antibiotics	  
5. Chronic	  infections	  treated	  with	  the	  protocol	  after	  
We	   count	   the	   number	   of	   primo-­‐infections	   for	   these	   five	   categories.	   For	   the	   concerned	  
patients,	  we	  put	  how	  many	  primo-­‐infections	  they	  had	  in	  each	  category.	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3 RESULTS	  
56	  patients	  were	  followed	  from	  June	  1st	  2007	  to	  June	  1st	  2011	  in	  the	  paediatric	  CF	  outpatient	  
clinic	  at	  Lausanne	  University	  Hospital	  in	  Switzerland.	  
41	  patients	  (73.2%)	  suffered	  from	  one	  or	  more	  Pseudomonas	  spp	  infections	  during	  the	  study	  
period.	  
18	  patients	  fully	  followed	  our	  protocol	  (see	  part	  2.3.1).	  They	  had	  20	  primo-­‐infections.	  Data	  
from	   them	   will	   be	   analysed.	   However,	   among	   these	   18	   patients,	   10	   had	   other	   primo-­‐
infections	   with	   gathered	   –	   but	   not	   used	   –	   data,	   due	   to	   non-­‐PA	   or	   non-­‐specified	  
Pseudomonas	  infections,	  primo-­‐infections	  not	  completely	  treated	  by	  the	  protocol,	  infections	  
with	   incomplete	   data,	   infections	   treated	   by	   the	   protocol	   after	   an	   hospitalisation	   for	   i.v.	  
antibiotics,	  chronic	  infections	  treated	  by	  the	  protocol.	  
3.1 Included	  data	  
18	   patients	   fully	   followed	   our	   protocol	   according	   our	   definition	   (see	   part	   2.3.1).	   These	  
patients	  had	  20	  primo-­‐infections.	  
	  
Figure	  8:	  repartition	  of	  included	  patients	  and	  primo-­‐infections	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3.1.1 Primary	  outcome	  
3.1.1.1 Successes	  and	  failures	  in	  eradication	  
Success	   was	   accomplished	   in	   16	   primo-­‐infections	   (all	   overall	   rate	   of	   80%)	   in	   15	   patients	  
(aged	  from	  2.5	  to	  16.8	  years,	  mean	  ±	  SD	  =	  9.1	  ±	  4.6	  years).	  One	  of	  these	  15	  patients	  had	  a	  
further	  primo-­‐infection	  with	  a	  failure	  in	  eradication	  (see	  bellow).	  
• 7	  girls	  (aged	  from	  2.8	  to	  14.1	  years,	  mean	  ±	  SD	  =	  9.7	  ±	  4.8	  years)	  with	  1	  of	  them	  who	  
had	  2	  primo-­‐infections	  (at	  11	  and	  12	  years	  old),	  success	  rate	  of	  100%	  among	  girls.	  
• 8	  boys	   (aged	   from	  2.5	   to	  16.8	  years,	  mean	  ±	  SD	  =	  8.5	  ±	  4.5	  years),	   success	   rate	  of	  
66.6%	  for	  the	  boys.	  
4	  boys	  (aged	  from	  6	  to	  10.9	  years,	  mean	  ±	  SD	  =	  8.3	  ±	  2.5	  years)	  had	  a	  failure	  in	  treatment.	  
One	  of	  these	  four	  patients	  had	  a	  previous	  primo-­‐infection,	  successfully	  treated	  (see	  bellow).	  
The	  three	  others	  had	  1	  primo-­‐infection	  during	  the	  study.	  	  
3.1.2 Secondary	  outcomes	  
3.1.2.1 Diagnostic	  methods	  
In	   the	   “success”	   group,	   11	   primo-­‐infections	  were	   diagnosed	   by	   sputum	   samples	   (patients	  
aged	  from	  6.5	  to	  16.9	  years,	  mean	  ±	  SD	  =	  10.8	  ±	  3.3	  years)	  and	  5	  by	  throat	  swaps	  (patients	  
from	  2.5	  to	  13.8	  years,	  mean	  ±	  SD	  =	  5.2	  ±	  4.9	  years).	  
In	   the	   “failure”	   group,	   all	   primo-­‐infections	   were	   diagnosed	   by	   sputum	   samples	   (patients	  
aged	  from	  6	  to	  10.9	  years,	  mean	  ±	  SD	  =	  8.3	  ±	  2.5	  years).	  
3.1.2.2 Bacterial	  analysis	  
In	  the	  “success”	  group,	  bacterial	  analysis	  revealed	  15	  non-­‐mucoid	  PA	  (10	  by	  sputum	  samples,	  
5	   by	   throat	   swaps),	   and	  1	  mucoid	  PA	   (by	   sputum	   sample).	   In	   the	   “failure”	   group,	   sputum	  
samples	  showed	  initially	  4	  non-­‐mucoid	  PA.	  
Number	  of	  associated	  microbes	  in	  successfully	  treated	  primo-­‐infections:	  
• 1	  microbe	  in	  7	  primo-­‐infections	  (43.8%)	  
• 2	  microbes	  in	  4	  primo-­‐infections	  (25%)	  
• 3	  microbes	  in	  3	  primo-­‐infections	  (18.8%)	  
• 5	  microbes	  in	  2	  primo-­‐infections	  (12.5%)	  
In	   the	   “success”	   group,	   oropharyngeal	   flora	   is	   present	   in	   75%	   of	   primo-­‐infections.	   Other	  
concomitant	   microbes	   and	   their	   presence	   percentage	   for	   successfully	   treated	   primo-­‐
infections	  are:	  
• S.	  aureus,	  56.3%	  
• Others,	  56.3%	  
• H.	  influenzae,	  25%	  
50%	  of	  unsuccessfully	  primo-­‐infections	  are	  associated	  with	   the	  presence	  of	  oropharyngeal	  
flora.	  A.	  fumigatus	  is	  found	  in	  50%	  of	  primo-­‐infections	  with	  a	  failure	  in	  eradication.	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3.1.2.3 PA	  status	  one	  year	  before	  the	  protocol	  
In	   the	   “success”	   group,	   3	   out	   of	   15	   patients	   (20%)	   had	   a	   primo-­‐infection	   during	   the	   year	  
before	  inclusion	  according	  to	  our	  protocol	  (aged	  from	  4.3	  to	  13.8	  years,	  mean	  ±	  SD	  =	  10	  ±	  5.1	  
years):	  
• 1	  girl	  had	  2	  primo-­‐infections	  successfully	  treated,	  11	  months	  apart	  between	  positive	  
specimens	  (both	  included	  in	  our	  results).	  
• 1	   girl	   had	   a	   primo-­‐infection	   successfully	   treated	   6	   months	   before,	   but	   not	   by	   the	  
protocol	  (not	  included	  in	  our	  results).	  
• 1	   boy	   were	   hospitalized	   and	   successfully	   treated	   for	   a	   primo-­‐infection	   11	  months	  
before	  (not	  included	  in	  our	  results).	  
In	  the	  “failure”	  group,	  none	  of	  the	  4	  boys	  had	  a	  primo-­‐infection	  the	  year	  before.	  
3.1.2.4 PA	  status	  one	  year	  after	  the	  protocol	  
In	  the	  “success”	  group,	  11	  (73.3%)	  patients	  out	  of	  15	  remained	  free	  from	  PA.	  A	  new	  primo-­‐
infection	   during	   the	   first	   year	   after	   the	   treatment	  was	   experienced	   by	   4	   (26.7%)	   patients	  
(exclusion	   of	   6	   months	   after	   the	   beginning	   of	   the	   protocol,	   see	   part	   2.5.3).	   In	   these	   4	  
patients	  (aged	  from	  4.3	  to	  16.8	  years,	  mean	  ±	  SD	  =	  11.5	  ±	  5.4	  years):	  
• 1	  girl	  followed	  successfully	  a	  second	  eradication	  protocol	  9	  months	  after	  (included	  in	  
our	  results).	  She	  had	  a	  third	  primo-­‐infection	  with	  incomplete	  data	  8	  months	  after	  the	  
beginning	  of	  the	  successful	  second	  eradication	  protocol	  (not	  included	  in	  our	  results).	  
• 1	  girl	  was	  hospitalized	  for	  a	  new	  primo-­‐infection	  10	  months	  after	  (not	  included	  in	  our	  
results).	  
• 1	  boy	  followed	  an	  incomplete	  protocol	  10	  months	  after	  (not	  included	  in	  our	  results).	  
• One	  year	  after,	  1	  boy	  was	  hospitalized	  with	  i.v.	  antibiotics	  for	  3	  PA	  that	  were	  finally	  
eradicated	  (not	  included	  in	  our	  results).	  More	  than	  two	  years	  after,	  he	  followed	  the	  
protocol	  with	  a	  failure	  in	  eradication	  (included	  in	  our	  results).	  
3	  boys	  (75%)	  who	  had	  a	  failure	  in	  eradication	  were	  hospitalized	  for	  i.v.	  antibiotics.	  They	  were	  
successfully	  treated	  and	  remain	  free	  from	  PA	  during	  the	  year	  after.	  Despite	  a	  hospitalisation,	  
1	  (25%)	  other	  boy	  with	  a	  failure	  of	  the	  protocol	  still	  had	  positive	  bacteriologies	  for	  PA	  during	  
the	  year	  after.	  
3.1.2.5 FEV1	  %	  
In	  the	  “success”	  group,	  the	  mean	  baseline	  FEV1	  %	  was	  102.3	  ±	  12.8,	  with	  a	  median	  of	  101.5.	  
After	   the	   treatment,	   the	  mean	  FEV1	  %	   is	  100	  ±	  14.7,	  with	  a	  median	  of	  100.	  T-­‐test	  =	  0.90.	  
Data	  for	  FEV1	  %	  were	  not	  available	  for	  4	  primo-­‐infections.	  
In	   the	   “failure”	   group,	   the	  mean	  baseline	   FEV1	  %	  was	  99.8	  ±	  21.6,	  with	   a	  median	  of	   100.	  
After	  the	  treatment,	  the	  mean	  FEV1	  %	  is	  92.6	  ±	  15,	  with	  a	  median	  of	  92.5.	  T-­‐test	  =	  0.96.	  Data	  
were	  available	  for	  all	  primo-­‐infections.	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3.1.2.6 BMI	  
Among	  the	  successfully	  treated	  primo-­‐infections,	  the	  mean	  baseline	  BMI	  was	  16.6	  ±	  3,	  with	  
a	  median	  of	  15.8.	  After	  the	  protocol,	  the	  mean	  BMI	  is	  16.9	  ±	  3.2,	  with	  a	  median	  of	  15.9.	  T-­‐	  
test	  =	  0.12.	  Data	  for	  BMI	  were	  not	  available	  for	  2	  primo-­‐infections	  (3.3%).	  
Among	  the	  primo-­‐infections	  with	  a	  failure	  in	  eradication,	  the	  mean	  baseline	  BMI	  was	  16.1	  ±	  
0.3,	  with	  a	  median	  of	  16.1.	  After	  the	  protocol,	  the	  mean	  BMI	  is	  16.5	  ±	  0.6,	  with	  a	  median	  of	  
16.4.	  T-­‐test	  =	  1.35.	  Data	  were	  available	  for	  all	  primo-­‐infections.	  
3.2 Excluded	  data	  	  
Among	  the	  18	  included	  patients,	  10	  had	  other	  infections	  with	  gathered	  –	  but	  not	  analysed	  –	  
data.	   10	   other	   patients	   had	   only	   gathered,	   but	   not	   used,	   data.	   These	   20	   patients	   had	   30	  
infections	  concordant	  with	  our	  exclusion	  criteria	  (see	  part	  2.3.2):	  
• 10	   non-­‐PA	   or	   non-­‐specified	   Pseudomonas	   infections	   treated	   by	   our	   eradication	  
protocol	  
• 9	  infections	  not	  completely	  treated	  by	  the	  protocol	  
• 2	  infections	  with	  incomplete	  data	  
• 3	   infections	   treated	   by	   the	   protocol,	   however	   after	   a	   hospitalisation	   for	   i.v.	  
antibiotics	  
• 6	  chronic	  infections	  treated	  with	  the	  protocol	  after	  
13	  patients	  had	  infections	  not	  treated	  by	  our	  protocol	  (for	  instance,	  by	  colistin).	  Data	  from	  
these	  patients	  were	  not	  gathered	  and	  not	  analysed.	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3.3 Results	  summary	  
	  
Table	  2:	  repartition	  of	  successes	  and	  failures	  
	  
Table	  3:	  repartition	  of	  girls	  and	  boys	  
	   	  
	  20	  
4 DISCUSSION	  
4.1 Included	  data	  
4.1.1 Primary	  outcome	  
4.1.1.1 Successes	  and	  failures	  in	  eradication	  
According	  our	  inclusion	  criteria,	  7	  girls	  (38.9%	  of	  our	  18	  patients)	  and	  11	  boys	  (61.1%	  of	  our	  
18	  patients)	  followed	  our	  eradication	  protocol.	  Boys	  had	  12	  primo-­‐infections	  and	  girls	  had	  8.	  
In	  applying	  our	  protocol,	  PA	  was	  eradicated	  all	  overall	  in	  80%	  of	  primo-­‐infections.	  However,	  
our	   study	   shows	  a	  difference	   in	  eradication	  between	  girls	   and	  boys.	   The	   success	   rate	  was	  
100%	  for	  girls	  and	  66.6%	  for	  boys.	  	  Mean	  ±	  SD	  age	  is	  9.1	  ±	  4.6	  years	  in	  the	  “success”	  group	  
and	  8.3	  ±	  2.5	  years	  in	  the	  “failure”	  group.	  There	  is	  no	  statistical	  difference	  in	  ages	  between	  
“success”	  and	  “failure”	  groups	  (t-­‐test	  =	  0.07	  with	  p	  =	  0.94).	  
In	   order	   to	   discuss	   these	   results,	   we	   focused	   our	   literature	   review	   on	   studies	   that	   used	  
inhaled	  tobramycin	  to	  treat	  PA	  primo-­‐infections.	  Several	   trials	  were	   identified	  (18-­‐24)	  with	  
two	  of	   these	   studies	   (18,19)	   referenced	   in	  2009	   in	  a	  Cochrane	   review,	  because	   they	  were	  
randomised,	  with	  a	  placebo	  group	  and	  from	  similar	  design	  (25).	  
Our	  literature	  review	  permits	  us	  first	  to	  legitimate	  our	  study	  by	  the	  fact	  that	  treatment	  of	  PA	  
primo-­‐infections	  is	  necessary.	  Gibson	  et	  al.	  (2003)	  demonstrated	  it.	  They	  compared	  28	  days	  
of	   inhaled	   tobramycin	   twice	  daily	   versus	  placebo.	   They	   randomized	  98	  patients.	  However,	  
they	  stopped	  their	  trial	  after	  an	  interim	  analyse	  of	  21	  patients	  (8	  in	  “treatment”	  group,	  13	  in	  
“placebo”	  group).	  This	  interim	  analyse	  showed	  that	  PA	  was	  eradicated	  in	  lower	  airways	  in	  all	  
patients	  in	  “treatment”	  group	  but	  only	  in	  1	  patient	  (7.4%)	  in	  “placebo”	  group	  (19).	  
Our	   protocol	   is	   started	   as	   soon	   as	   PA	   is	   diagnosed.	  We	   don’t	   use	   preventative	   cycles	   of	  
therapy	  without	  proof	   that	  PA	   is	   present,	   in	   concordance	  with	  Treggiari	   et	   al.	   (2011)	  who	  
showed	   that	   inhaled	   tobramycin	   should	   be	   prescribed	   only	  when	  PA	   is	   detected	   to	   avoid	  
pulmonary	   exacerbation,	   instead	   of	   giving	   preventative	   cycled	   therapies	   in	   patients	   not-­‐
known	   for	   primo-­‐infections	   respectively	   chronic	   PA	   infections.	   Their	   trial	   compared	   4	  
regimens	   based	   on	   28	   days	   of	   inhaled	   tobramycin	   and	   14	   days	   of	   oral	   ciprofloxacin	   or	  
placebo:	   inhaled	   tobramycin	   once	   every	   3	   months	   (“cycled	   therapy”	   group)	   or	   when	   PA	  
culture	  is	  positive	  (“culture-­‐based”	  group),	  with	  oral	  ciprofloxacin	  (“ciprofloxacin”	  group)	  or	  
placebo	  (“placebo”	  group).	  16%	  patients	  in	  “cycled”	  group	  and	  17%	  in	  “culture-­‐based”	  group	  
had	  a	  severe	  pulmonary	  exacerbation	  requiring	  i.v.	  antibiotics	  or	  hospitalization	  (21).	  
Apart	  from	  an	  abstract	  presented	  in	  2012	  during	  the	  European	  Cystic	  Fibrosis	  Conference	  in	  
Dublin	   (26),	  we	   found	  no	  other	   study	  using	  our	  protocol.	  Moreover,	  only	  one	  of	   the	   trials	  
used	   the	   same	   endpoint	   with	   definition	   of	   success	   of	   eradication	   already	   after	   6	  months	  
without	  PA	  (22).	  There	  is	  no	  unified	  consensus	  about	  the	  duration	  of	  absence	  of	  PA	  to	  define	  
it	   as	   a	   success,	   but	   in	   most	   studies	   12	  months	   are	   chosen.	   This	   is	   problematic	   from	   our	  
clinical	  point	  of	  view	  as	  patients	  who	  received	  eradication	  treatment	  between	  one	  to	  three	  
months	  (19-­‐24)	  remain	  in	  the	  “PA	  positive”	  cohort	  for	  another	  9	  to	  11	  months	  –	  but	  without	  
treatment.	   During	   that	   time	   period,	   there	   is	   an	   increased	   risk	   to	   be	   re-­‐exposed	   to	  PA	   by	  
cross-­‐infection	  by	  contact	  with	  other	  PA	  positive	  patients	  (27)	  during	  outpatient	  clinic	  visits.	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Taccetti	  et	  al.	  (2012)	  used	  the	  same	  definition	  of	  duration	  of	  success	  as	  we	  did,	  comparing	  
28	  days	  of	   inhaled	   tobramycin	  and	  oral	   ciprofloxacin	   (“arm	  A”)	   versus	   inhaled	  colistin	  and	  
oral	   ciprofloxacin	   (“arm	   B”).	   Success	   in	   eradication	   was	   obtained	   in	   66	   on	   105	   patients	  
(62.8%)	  in	  “arm	  A”	  and	  in	  77	  on	  118	  patients	  (65.2%)	  in	  “arm	  B”	  with	  conclusion	  that	  there	  
was	  no	  statistical	  difference	  in	  these	  protocols	  (22).	  
If	  we	  focus	  on	  “arm	  A”,	  we	  see	  that	  our	  results	  are	  better	  (80%	  versus	  
62.8%).	  However,	  Taccetti	  et	  al.	   (2012)	  were	  aware	  that	  their	  results	  
were	  not	   as	   good	  as	   in	   other	   studies	   probably	   due	   to	  differences	   in	  
the	  design	  of	  studies,	  differences	   in	   the	  protocols,	   follow-­‐up,	  …	   (22).	  
We	   conducted	   a	   single	   centre	   and	   retrospective	   study,	   but	   able	   to	  
analyse	   data	   for	   18	   patients	   only.	   Taccetti	   et	   al.	   (2012)	   involved	   13	  
centres	  and	  randomised	  223	  patients.	  He	  used	  a	  28	  days	  protocol	  of	  
inhaled	  tobramycin	  (22),	  which	  is	  shorter	  than	  ours	  (84	  days).	  It	  could	  
explain	  the	  difference	  in	  the	  results.	  
Wiesemann	  et	  al.	   (1998)	  compared	  80	  mg	  of	  aerosolized	  tobramycin	  
twice	   a	   day	   for	   12	   months	   versus	   placebo.	   They	   reported	   that	   the	  
mean	  time	  necessary	  for	  conversion	  from	  PA	  positive	  to	  PA	  negative	  
in	   cultures	   was	   1.89	   month	   (roughly	   56	   days)	   in	   the	   aerosolized	  
tobramycin	   group	   and	   not	   assessable	   in	   the	   placebo	   group	   (18).	  
However,	   Ratjen	   et	   al.	   (2010)	   evaluated	   28	   days	   versus	   56	   days	   of	  
inhaled	   tobramycin	   twice	  a	  day.	  They	   randomised	  88	  patients	   (45	   in	  
“28-­‐days”	  group	  and	  43	  in	  “56-­‐days”	  group).	  They	  analysed	  data	  from	  
65	   of	   them	   (34	   in	   “28-­‐days”	   group	   and	   31	   in	   “56-­‐days”	   group)	   and	  
reported	   that	   the	   time	   to	   recurrence	   was	   26.12	   months	   (in	   “28-­‐days”	   group)	   and	   25.82	  
months	  (in	  “56-­‐days”	  group),	  not	  statistically	  significant	  (20).	  Moreover,	  Gibson	  et	  al.	  (2007)	  
compared	  28	  days	  of	  inhaled	  tobramycin	  with	  56,	  84	  or	  112	  days	  of	  follow-­‐up	  and	  56	  days	  of	  
inhaled	   tobramycin	   with	   112	   days	   of	   follow-­‐up.	   Their	   study	   showed	   a	   similar	   rate	   in	  
eradication:	  75%	  in	  28	  days	  of	  inhaled	  tobramycin	  and	  56	  days	  of	  follow-­‐up,	  63%	  in	  28	  days	  
of	  inhaled	  tobramycin	  and	  84	  days	  of	  follow-­‐up,	  75%	  in	  28	  days	  of	  inhaled	  tobramycin	  and	  
112	  days	  of	  follow-­‐up,	  82%	  in	  56	  days	  of	  inhaled	  tobramycin	  and	  112	  days	  of	  follow-­‐up	  (23).	  	  
Our	  study	  and	  Taccetti	  et	  al.	  (2012)	  trial	  include	  oral	  ciprofloxacin	  (22).	  However,	  Treggiari	  et	  
al.	  (2011)	  demonstrated	  that	  oral	  ciprofloxacin	  during	  14	  days	  give	  no	  benefice	  in	  addition	  to	  
28	   days	   of	   inhaled	   tobramycin.	   They	   showed	   no	   statistical	   significant	   difference	   in	  
pulmonary	  exacerbations	  for	  patient	  on	  inhaled	  tobramycin	  with	  oral	  ciprofloxacin	  (19%)	  or	  
placebo	  (14%)	  (21).	  	  
Our	  success	  rate	   in	  eradication	  for	  girls	  was	  100%.	  The	  success	  rate	  for	  boys	   is	  with	  66.6%	  
close	   to	   the	   global	   success	   rate	   in	   eradication	   in	   Taccetti	   et	   al.	   (2012)	   trial	   (62.8%)	   (22).	  
However,	   neither	   this	   study	   (22)	   nor	   the	   others	   (18-­‐21,23-­‐24)	   reported	   differences	   in	  
eradication	   according	   to	   the	   sex	   of	   patients.	   An	   explanation	   for	   our	   results	  might	   be	   the	  
excess	  of	  boys	   (11	   compared	   to	  7	  girls).	   There	   is	   a	   slight	  difference	   in	   the	  mean	  ±	  SD	  age	  
according	   to	   the	   sex	   –	   for	   boys,	   8.4	   ±	   3.8	   years	   and	   for	   girls,	   9.7	   ±	   4.8	   years	   –	   however	  
without	  significant	  statistical	  difference	  (t-­‐test	  =	  0.15	  with	  p	  <	  0.05).	  The	  number	  of	  previous	  
primo-­‐infections	   is	   neither	   an	   explanation	   too.	   Only	   one	   of	   the	   patients	   with	   a	   failure	   in	  
eradication	  had	  a	  primo-­‐infection	  before.	  Finally,	  all	  boys	  in	  the	  “failure”	  group	  are	  known	  to	  
be	  either	  non-­‐compliant	  or	  to	  have	  social	  familial	  difficulties.	  	  
Table	  4:	  successes	  and	  
failures	  key	  points	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Before	   inhaled	   tobramycin	   was	   available,	   colistin	   was	   used	   to	   treat	   PA	   primo-­‐infections.	  
Some	  studies	  evaluated	  the	  efficacy	  of	  colistin	   (28-­‐31).	  Taccetti	  et	  al.	   (2012)	  used	   it	   in	   the	  
“arm	  B”	  of	  their	  trial.	  They	  get	  65.2%	  of	  successes	  in	  eradication	  in	  “arm	  B”	  versus	  62.8%	  in	  
“arm	  A”,	  with	  no	  statistical	  difference	  between	  the	  two	  groups	  (22).	  Proesmans	  et	  al.	  (2012)	  
compared	   28	   days	   inhaled	   tobramycin	   (“TOBI”	   group)	   versus	   inhaled	   colistin	   with	   oral	  
ciprofloxacin	   for	  3	  months	   (“CC”	  group)	  too.	  At	  the	  end	  of	   the	  treatment,	  6	  on	  29	  (89.7%)	  
were	   successfully	   treated	   in	   “CC”	   group	   and	   23	   on	   29	   primo-­‐infections	   (79.3%)	   in	   “TOBI”	  
group.	  6	  months	  after	  the	  inclusion	  in	  the	  study,	  19	  primo-­‐infections	  (65.5%)	  in	  “CC”	  group	  
remained	   free	   from	   PA	   and	   13	   (44.8%)	   in	   “TOBI”	   group.	   They	   concluded	   that	   both	  
treatments	   are	   equivalent	   (24).	   There	   is	   no	   indication	   to	   considerate	   the	   use	   of	   colistin	  
instead	   of	   tobramycin.	   Taccetti	   et	   al.	   (2012)	   and	   Proesmans	   et	   al.	   (2012)	   confirmed	   that	  
tobramycin	   protocols	   based	   are	   as	   effective	   as	   colistin	   protocols	   based	   indeed	   (22,24).	  
Moreover,	   Proesmans	   et	   al.	   (2012)	   demonstrated	   that	   a	   tobramycin	   protocol	   based	  of	   28	  
days	  is	  as	  efficient	  as	  a	  colistin	  protocol	  based	  of	  3	  months	  (24).	  
4.1.2 Secondary	  outcomes	  
4.1.2.1 Diagnostic	  methods	  
To	   perform	   PA	   diagnosis,	   sputum	   samples	   and	   throat	   swaps	   were	  
used.	   Sputum	   samples	   were	   positive	   in	   identification	   of	   15	   primo-­‐
infections	  (75%)	  and	  throat	  swaps	  in	  5	  (25%).	  
Patient	  s	  that	  expectorated	  were	  older	  (mean	  ±	  SD	  =	  10.2	  ±	  3.2	  years,	  
min	  =	  6	  years,	  max	  =	  16.8	  years)	  than	  patients	  in	  whom	  throat	  swaps	  
were	  performed	  (mean	  ±	  SD	  =	  5.2	  ±	  4.9	  years,	  min	  =	  2.5	  years,	  max	  =	  
13.8	   years).	   The	   age	   difference	   was	   anticipated	   because	   young	  
patients	  are	  not	  able	  to	  expectorate.	  	  
A	  recent	  trial	  demonstrated	  that	  bronchoalveolar	  lavage	  is	  not	  better	  
than	   other	   technics	   such	   as	   throat	   swaps	   and	   sputum	   samples	   to	  
diagnose	   bacterial	   aetiologies	   in	   case	   of	   a	   pulmonary	   exacerbation	  
(17).	  	  
4.1.2.2 Bacterial	  analysis	  
All	   patients	   had	  minimum	  one	   concomitant	  microbe,	   independent	   of	   success	   or	   failure	   in	  
eradication.	  With	  exception	  of	  PA,	  using	  standard	  bacteriological	  or	  fungal	  cultures,	  only	  one	  
microbe	  was	  identified	  in	  62.1%	  of	  all	  our	  primo-­‐infections,	  2	  microbes	  in	  22.2%,	  3	  microbes	  
in	  16.7%	  and	  lastly	  5	  microbes	  in	  11.1%.	  
For	  both	  groups,	  S.	  aureus	  was	   the	  most	  often	   found	  concomitant	  microbe,	   in	  45%	  of	  our	  
primo-­‐infections,	   followed	  by	  20%	  of	  H.	   influenzae,	  15%	  of	  A.	   fumigatus.	  Other	  pathogens	  
were	  concomitant	   in	  40%	  of	  our	  primo-­‐infections.	  Oropharyngeal	  flora	  was	  present	   in	  70%	  
of	   all	   our	   primo-­‐infections.	   All	   primo-­‐infections	   in	   the	   “failure”	   group	   had	   one	   (100%)	  
concomitant	   pathogen.	   Primo-­‐infections	   in	   “success”	   group	   had	   one	   (43.8%)	   and	   more	  
(56.3%)	  concomitant	  pathogens.	  
Wiesemann	  et	  al.	  (1998)	  reported	  S.	  aureus	  and	  H.	  influenzae	  as	  concomitant	  phatogens,	  S.	  
maltophilia	   and	   Enterobacteriaceae	   spp	   were	   isolated	   as	   well	   (18).	   Ratjen	   et	   al.	   (2010)	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isolated	   in	   their	   both	   groups	  S.	   aureus	   in	   39.5%,	  H.	   influenzae	   in	   14%,	  C.	   albicans	   in	   11%,	  
Aspergillus	   spp	   in	   9%,	   S.	   maltophilia	   in	   4.5%	   of	   their	   cases	   (20).	   Treggiari	   et	   al.	   (2012)	  
described	   the	   following	   concomitant	   pathogens	   among	   their	   4	   groups:	   S.	   aureus	   58%,	   S.	  
maltophilia	  3.5%,	  A.	  xylosoxidans	  1%,	  B.	  cepecia	  complex	  0.75%	  (21).	  Taccetti	  et	  al.	   (2012)	  
isolated	   those	   pathogens	   in	   their	   two	   groups:	   S.	   aureus	   30%,	   H.	   influenzae	   9.8%,	   S.	  
pneumoniae	  0.8%	  (22).	  Gibson	  et	  al.	  (2007)	  had	  S.	  aureus	  (32%),	  H.	  influenzae	  (29%),	  and	  S.	  
pneumoniae	  (18%)	  as	  concomitant	  pathogens	  (23).	  
In	  conclusion,	  most	  of	   these	  studies,	  as	  ours,	  often	   isolated	  S.	  aureus	  and	  H.	   influenzae	  as	  
concomitant	  pathogens.	  If	  concomitant	  pathogens	  are	  a	  precursor	  for	  PA	  infections	  remains	  
however	  a	  matter	  of	  debate	  at	  current	  time.	  
	  
Table	  6:	  bacterial	  analysis	  key	  points	  
4.1.2.3 PA	  status	  1	  year	  before	  the	  treatment	  
20%	   of	   patients	   in	   the	   “success”	   group	   but	   none	   in	   the	   “failure”	   group	   had	   a	   PA	   primo-­‐
infection	  during	  the	  year	  before	  the	  beginning	  of	  the	  protocol.	  It	  concerns	  15%	  of	  all	  overall	  
patients	  (n	  =	  18).	  
Proesmans	   et	   al.	   (2012)	   included	   patients	   with	   first	   ever	   or	   new	   primo-­‐infections.	   A	   new	  
primo-­‐infection	  was	  defined	  after	  minimum	  6	  months	  PA	   free.	  6	  patients	  on	  19	   (31.6%)	   in	  
the	  “CC”	  group	  and	  3	  on	  21	   (14.3%)	   in	   the	  “TOBI”	  group	  had	  a	  primo-­‐infection	  during	   the	  
year	  before	  (24),	  the	  latter	  14.3%	  is	  close	  to	  our	  20%.	  
Taccetti	  et	  al.	  (2012)	  recruited	  patients	  with	  first	  ever	  primo-­‐infections	  or	  with	  new	  primo-­‐
infections	   successfully	   treated	   and	   with	   3	   negative	   cultures	   during	   6	   months.	   Rate	   in	  
eradication	  was	   similar	   for	   patients	  with	   first	   ever	   primo-­‐infections	   (66.1%)	   and	  with	   new	  
primo-­‐infections	   (61.7%),	   but	   they	   didn’t	   gave	   detailed	   data	   on	  primo-­‐infections	   the	   year	  
before	  (22),	  therefore	  we	  can’t	  compare	  our	  result	  (20%)	  to	  this	  study.	  
Wiesemann	  et	  al.	  (1998),	  Gibson	  et	  al.	  (2003	  and	  2007),	  Ratjen	  et	  al.	  (2010)	  and	  Treggiari	  et	  
al.	  (2011)	  didn’t	  have	  data	  for	  this	  particular	  point	  we	  can	  compare	  to	  ours	  because	  of	  their	  
criteria	  of	  inclusion	  (18-­‐21,23).	  
4.1.2.4 PA	  status	  1	  year	  after	  the	  treatment	  
73.3%	   of	   our	   patients	   remained	   PA	   free	   one	   year	   after	   the	   beginning	   of	   the	   successful	  
treatment,	  in	  comparison	  to	  80%	  after	  6	  months,	  leading	  to	  4	  patients	  who	  re-­‐acquired	  PA	  
between	  6	  to	  12	  months	  after	  the	  start	  of	  the	  eradication	  therapy.	  75%	  of	  our	  patients	  with	  
a	   failure	   of	   the	   protocol	   –	   and	   then	   successfully	   treated	   after	   a	   course	   of	   two	  weeks	   i.v.	  
antibiotics	  –	  were	  free	  of	  PA	  one	  year	  after	  the	  beginning	  of	  the	  protocol.	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Wiesemann	   et	   al.	   (1998)	   treated	   their	   cohort	   for	   one	   year.	   At	   the	   end	   of	   the	   treatment	  
period,	   8/9	   patients	   (88.9%)	   in	   the	   “tobramycin”	   group	   were	   free	   of	   PA,	   but	   only	   1/5	  
patients	   (20%)	   in	  “placebo”	  group.	  Their	   rate	  of	  patients	   free	  of	  PA	   (88.9%)	   is	  higher	   than	  
ours	  (73.3%),	  most	  likely	  due	  to	  the	  fact	  that	  the	  microbiological	  analysis	  was	  made	  directly	  
at	  the	  end	  of	  treatment,	  and	  not	  as	   in	  our	  study,	  7	  months	  after	  the	  end	  of	  the	  treatment	  
(18).	  
Taccetti	   et	   al.	   (2012)	   reported	   data	   about	   PA	   status	   6	   months	   after	   the	   end	   of	   their	  
treatments,	  with	   66	   patients	   out	   of	   105	   (62.9%)	   in	   “arm	  A”	   and	   77	   out	   of	   118	   (65.3%)	   in	  
“arm	  B”	  remained	  free	  of	  PA	  in	  the	  first	  year	  (22).	  	  
Gibson	  et	  al.	  (2003	  and	  2007)	  had	  no	  data	  concerning	  the	  PA	  status	  after	  one	  year	  (19,23).	  
Ratjen	   et	   al.	   (2010)	   demonstrated	   a	   time	   to	   recurrence	  of	   26.12	  months	   in	   the	   “28-­‐days”	  
group	  and	  of	  25.82	  months	  in	  the	  “56-­‐days”	  group.	  They	  didn’t	  present	  results	  on	  PA	  status	  
after	  one	  year	   (20).	  Data	   for	  PA	  status	  after	  one	  year	  weren’t	  available	   for	  Treggiari	  et	  al.	  
(2011)	  trial	  (21).	  
	  
Table	  7:	  PA	  status	  1	  year	  before	  and	  after	  the	  beginning	  of	  the	  treatment	  key	  points	  
4.1.2.5 FEV1	  %	  
We	  found	  no	  significant	  changes	  in	  FEV1	  %	  values	  after	  the	  treatment	  neither	   in	  “success”	  
nor	  in	  “failure”	  groups	  (“Success”	  group:	  t-­‐test	  =	  0.9,	  p	  =	  0.39,	  “failure”	  group:	  t-­‐test	  =	  0.96,	  
p	  =	  0.41).	  
Wiesemann	  et	  al.	  (1998)	  didn’t	  present	  data	  concerning	  variation	  in	  FEV1	  (18).	  Ratjen	  et	  al.	  
(2010)	  didn’t	  observe	  any	   changes	   in	  FEV1	  values	   in	   their	  both	  groups	  of	   their	   study	   (20).	  
Treggiari	  et	  al.	  (2011)	  reported	  no	  difference	  in	  FEV1	  values	  across	  their	  4	  treatments	  groups	  
(21).	  
Taccetti	  et	  al	  (2012)	  however	  observed	  an	  increase	  of	  FEV1	  values	  in	  both	  “arm	  A”	  and	  “arm	  
B”	  (22).	  During	  the	  year	  or	  their	  study,	  Proesmans	  et	  al.	  (2012)	  observed	  a	  median	  change	  of	  
-­‐1%	  in	  both	  groups	  (24).	  
Gibson	  et	  al.	  (2003	  and	  2007)	  reported	  nothing	  on	  FEV1	  values	  (19,23).	  
4.1.2.6 BMI	  
We	   found	   no	   significant	   changes	   in	   BMI	   values	   before	   and	   after	   the	   treatment,	   in	   both	  
groups.	  (“Success”	  group:	  t-­‐test	  =	  0.12,	  p	  =	  0.91;	  “failure”	  group:	  t-­‐test	  =	  1.35,	  p	  =	  0.27).	  
Ratjen	  et	  al.	  (2010)	  didn’t	  observe	  any	  influence	  of	  theirs	  treatments	  (28	  days	  tobramycin	  or	  
56	   days)	   on	   BMI	   values	   (20).	   Treggiari	   et	   al.	   (2011)	   didn’t	   note	   statistically	   significant	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variation	  in	  weight	  and	  height	  among	  their	  4	  different	  groups	  (21).	  Proesmans	  et	  al.	  (2012)	  
didn’t	  observe	  a	  significant	  change	  in	  BMI	  values	  in	  their	  groups	  during	  the	  year	  of	  their	  trial	  
(24).	  
Gibson	   et	   al.	   (2003)	   mentioned	   that	   differences	   in	   weight	   were	   similar	   in	   “tobramycin”	  
group	  and	  in	  “placebo”	  group,	  but	  no	  BMI	  data	  were	  available	  (19).	  Studies	  from	  Wiesemann	  
et	  al.	  (1998),	  Gibson	  et	  al.	  (2007)	  and	  Taccetti	  et	  al.	  (2012)	  didn’t	  present	  any	  data	  on	  BMI	  
(18,22-­‐23).	  
	  
Table	  8:	  FEV1	  %	  and	  BMI	  values	  key	  points	  
4.2 Excluded	  data	  
Excluded	  data	  will	  not	  be	  discussed	  further	  in	  detail.	  
4.3 Limitations	  of	  our	  study	  
A	   clear	   limitation	   of	   our	   study	   is	   the	   very	   small	   sample	   size	   (18	   patients,	   with	   20	   primo-­‐
infections).	  Other	  studies	  had	  much	  more	  participants	  (20-­‐24).	  The	  design	  of	  the	  study	  itself	  
is	  a	  limitation	  too.	  Our	  study	  is	  retrospective	  and	  focus	  only	  on	  a	  shorter	  time	  (4	  years),	  than	  
other	  trials	  (20,21,24).	  We	  have	  no	  control	  group	  in	  our	  study.	  All	  the	  trials	  we	  identified	  by	  
literature	   review	   had	   more	   than	   one	   arm	   (18-­‐24).	   Moreover,	   some	   of	   these	   trials	   were	  
randomised	  and	  double	  blinded	  (18-­‐19).	  In	  those	  patients	  who	  experienced	  some	  time	  ago	  a	  
PA	  infection,	  to	  define	  a	  true	  new	  primo-­‐infection,	  genotyping	  of	  PA	  might	  be	  helpful.	  This	  is	  
however	  not	  available	  in	  our	  routine	  bacterial	  analysis.	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5 CONCLUSION	  
We	  achieved	  an	  eradication	  rate	  of	  100%	  in	  girls	  using	  our	  protocol,	  with	  an	  overall	  rate	  of	  
80%	  for	  PA	  eradication.	  Our	  results	  are	  difficult	  to	  compare	  to	  other	  studies,	  because	  we	  did	  
not	  identify	  another	  trial	  using	  our	  eradication	  protocol	  (18-­‐24),	  apart	  from	  the	  group	  from	  
the	   Royal	   Children’s	   Hospital	   in	   Melbourne,	   who	   presented	   their	   data	   with	   an	   abstract	  
during	   the	  European	  Cystic	   Fibrosis	  Conference	  2012	   in	  Dublin	   (26).	  And	   just	  one	  had	   the	  
same	   outcome	   of	   success	   in	   defining	   success	   of	   eradication	   six	  months	   after	   the	   start	   of	  
treatment	  (22).	  But	  our	  66.6%	  eradication	  rate	  for	  boys	  is	  similar	  to	  the	  60%	  for	  the	  inhaled	  
tobramycin	  arm	  in	  this	  study	  (22).	  However,	  none	  of	  the	  studies	  we	  focus	  on	  analysed	  the	  
rate	   in	   eradication	   according	   to	   the	   sex	   (18-­‐24).	   Why	   this	   success	   in	   girls?	   We	   can	   only	  
speculate	  on	  this.	  Is	  it	  due	  to	  the	  fact	  that	  there	  were	  more	  boys	  in	  our	  study	  than	  girls	  (11	  
boys	  vs	  7	  girls)?	  Are	  pre-­‐pubertal	  girls	  more	  compliant	  with	  therapy,	  or	  better	  supervised	  by	  
caregivers	   than	  boys?	   Is	   there	   a	   difference	   in	   the	  microbiome	   in	   girls	   comparing	   to	  boys?	  
Although	   our	   sample	   size	   was	   very	   small,	   the	   sex	   difference	  merits	   certainly	   attention	   in	  
further	  prospective	  eradication	  studies,	  if	  not	  a	  data	  analysis	  according	  to	  sex	  could	  be	  done	  
in	  the	  studies	  already	  published.	  
Our	  literature	  review	  permits	  us	  to	  assess	  the	  pertinence	  of	  our	  protocol.	  One	  of	  these	  trials	  
confirmed	  that	  PA	  antibiotics	  treatment	  is	  better	  than	  placebo	  (19)	  and	  another	  one	  that	  the	  
treatment	   should	   be	   started	   only	   once	   the	   pathogens	   is	   diagnosed	   by	  microbiology	   (21).	  
These	  studies	  are	  the	  proof	  we	  need	  to	  continue	  to	  perform	  frequent	  microbiology	  analysis	  
in	  our	  patients	  and	  keep	  on	  going	  our	  protocol	  only	  if	  PA	  is	  present,	  particularly	  in	  girls.	  An	  
initial	  i.v.	  therapy	  of	  two	  weeks	  has	  probably	  to	  be	  considered	  in	  case	  of	  PA	  primo-­‐infections	  
in	  boys	  with	  already	  knowledge	  about	  possible	  problem	  of	  compliance.	  
Two	   other	   studies	   showed	   that	   there	   is	   no	   difference	   between	   28	   or	   56	   days	   of	   inhaled	  
tobramycin	   (20,23).	   Moreover,	   a	   study	   found	   no	   difference	   in	   pulmonary	   exacerbations	  
using	  ciprofloxacin	  or	  not	  (21).	  Both	  the	  points	  of	  duration	  of	  inhaled	  tobramycin	  and	  use	  of	  
oral	  ciprofloxacin	  should	  be	  further	  analysed	  in	  future	  studies	  to	  avoid	  overuse	  of	  antibiotics	  
and	  the	  emergence	  of	  resistances.	  
Two	   studies	   showed	   that	   inhaled	   colistin	   is	   as	   efficient	   as	   inhaled	   tobramycin	   (22,24),	   but	  
with	  colistin	  available	  by	  inhalation	  for	  a	  longer	  time	  (28-­‐31).	  As	  mentioned	  already,	  the	  fact	  
we	  had	  no	  comparison	  group	  in	  our	  study	  was	  a	  clear	  limitation.	  In	  a	  further	  trial,	  we	  could	  
envisage	  to	  treat	  patients	  by	  inhaled	  colistin	  in	  a	  potential	  comparison	  group.	  
To	  conclude,	  our	  overall	  eradication	  rate	   is	  80%.	  However,	  we	  found	  a	  difference	  between	  
girls	  and	  boys	  (100%	  vs	  66.6%).	  This	  difference	  should	  be	  investigated	  in	  further	  studies,	  as	  
the	  duration	  of	  inhaled	  tobramycin	  versus	  colistin	  and	  the	  addition	  of	  oral	  ciprofloxacin.	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